Our current focus is on pancreatic cancer, but our R&D efforts span across multiple additional cancer types, including ovarian – another high-mortality cancer due to late detection. ClearNote Health is focused on cancers with high mortality rates for which there are very limited detection options. These are cancers that often go undiagnosed until late stage, thus limiting patients’ treatment options and long-term survival.

Our first product– the Avantect Pancreatic Cancer Test –is a test for patients at high risk for pancreatic cancer, including those newly diagnosed with type 2 diabetes age 50+. The Avantect test detects pancreatic cancer in its earliest stages by measuring levels of the biomarker 5-hydroxymethylcytosine (5hmC) using a simple blood draw. Pancreatic cancer is one of the deadliest cancers, because it is often diagnosed too late for patients to receive effective treatment and patients newly diagnosed with type 2 diabetes are 8 times as likely to develop pancreatic cancer as the general population.

We are also developing targeted multi-cancer test panels to detect several different cancers through a single blood draw.